BioNTech (NASDAQ:BNTX) Hits New 12-Month Low at $84.57

BioNTech SE (NASDAQ:BNTX)’s share price reached a new 52-week low during mid-day trading on Friday . The company traded as low as $84.57 and last traded at $84.74, with a volume of 201824 shares trading hands. The stock had previously closed at $85.88.

Analyst Ratings Changes

A number of research analysts have issued reports on the stock. JPMorgan Chase & Co. cut their target price on shares of BioNTech from $99.00 to $90.00 and set an “underweight” rating on the stock in a research report on Friday, March 22nd. BMO Capital Markets cut their target price on shares of BioNTech from $123.00 to $122.00 and set an “outperform” rating on the stock in a research report on Tuesday, May 7th. UBS Group lowered their price target on BioNTech from $110.00 to $101.00 and set a “neutral” rating for the company in a research note on Wednesday, March 27th. HC Wainwright reaffirmed a “buy” rating and issued a $113.00 price target on shares of BioNTech in a research note on Monday, June 10th. Finally, TD Cowen upped their price target on BioNTech from $95.00 to $98.00 and gave the company a “hold” rating in a research note on Tuesday, May 7th. One equities research analyst has rated the stock with a sell rating, six have issued a hold rating and three have given a buy rating to the company’s stock. According to data from MarketBeat.com, BioNTech presently has a consensus rating of “Hold” and a consensus price target of $111.70.

BioNTech Trading Down 1.4 %

The business has a 50 day moving average of $92.61 and a 200-day moving average of $95.31. The company has a current ratio of 11.38, a quick ratio of 11.16 and a debt-to-equity ratio of 0.01. The firm has a market capitalization of $20.12 billion, a P/E ratio of 169.28 and a beta of 0.27.

BioNTech (NASDAQ:BNTX) last posted its earnings results on Monday, May 6th. The company reported ($1.42) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.82) by ($0.60). The business had revenue of $203.69 million for the quarter, compared to the consensus estimate of $589.96 million. BioNTech had a return on equity of 0.55% and a net margin of 4.01%. Analysts anticipate that BioNTech SE will post -2.01 EPS for the current fiscal year.

Hedge Funds Weigh In On BioNTech

Several hedge funds have recently made changes to their positions in BNTX. GAMMA Investing LLC grew its stake in shares of BioNTech by 121.0% during the 1st quarter. GAMMA Investing LLC now owns 274 shares of the company’s stock worth $25,000 after acquiring an additional 150 shares in the last quarter. CWM LLC boosted its holdings in shares of BioNTech by 657.6% in the 4th quarter. CWM LLC now owns 250 shares of the company’s stock valued at $26,000 after buying an additional 217 shares during the last quarter. Frazier Financial Advisors LLC acquired a new stake in shares of BioNTech in the 4th quarter valued at approximately $30,000. Covestor Ltd acquired a new stake in shares of BioNTech in the 3rd quarter valued at approximately $32,000. Finally, First Horizon Advisors Inc. acquired a new stake in shares of BioNTech in the 4th quarter valued at approximately $38,000. 15.52% of the stock is owned by institutional investors.

About BioNTech

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.